Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $39.50

Shares of Urogen Pharma (NASDAQ:URGN) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $39.50.

URGN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Urogen Pharma in a report on Wednesday, June 3rd. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. Finally, Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00. Following the sale, the insider directly owned 129,763 shares of the company’s stock, valued at approximately $4,543,002.63. The trade was a 7.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in URGN. Osaic Holdings Inc. boosted its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares during the period. Finally, Nebula Research & Development LLC purchased a new position in Urogen Pharma during the second quarter valued at $162,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $38.03 on Friday. The firm has a market cap of $1.85 billion, a P/E ratio of -13.83 and a beta of 1.56. Urogen Pharma has a fifty-two week low of $13.55 and a fifty-two week high of $39.58. The business’s 50 day moving average price is $30.66 and its 200-day moving average price is $24.21.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. As a group, equities analysts predict that Urogen Pharma will post -0.88 EPS for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.